|
KMID : 1141720170050010010
|
|
폐쇄성폐질환
2017 Volume.5 No. 1 p.10 ~ p.10
|
|
|
|
|
Lee Jae-Seung
|
|
|
Abstract
|
|
|
|
A large amount of biomarkers has been evaluated in COPD patients. However, there are still no well validated biomarkers or surrogate endpoints that can be used to establish efficacy of novel drugs for COPD. Eosinophilic inflammation is thought to be a characteristic feature of asthma rather than COPD. However, studies have shown that a subset of COPD patients with eosinophilic airway inflammation exists. Higher sputum and blood eosinophil counts are associated with increased corticosteroid responsiveness in COPD patients. Recent studies suggest that blood eosinophils show promise to not only serve as a biomarker for predicting reduction in exacerbations with inhaled corticosteroid therapy but also as a biomarker for predicting risk of pneumonia with such therapy. A cutoff of 2% or more blood eosinophil seems to hold the most promise as a biomarker for prediction of several outcomes including exacerbation reduction, safe withdrawal of steroids, response to systemic steroids. Blood eosinophil measurements may be useful for selecting patients for different therapeutic approaches. However, there are still a number of issues that need to be resolved regarding eosinophils as biomarkers in COPD.
|
|
|
KEYWORD
|
|
|
COPD, Eosinophil, Biomarker, Steroid
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|